|
|
 |
|
Viewing report
|
|
|
|
Antivirals - A Broad Market Overview
Datamonitor, Aug 2003
Since the discovery of the first vaccination against an infectious disease (smallpox) by Edward Jenner in 1798, many additional vaccinations have been developed, dramatically decreasing incidence of viral infections such as measles, diphtheria and polio.
However, the treatment of viral infections has proved far less straightforward with the development of antiviral therapies lagging behind advances in other infectious disease fields.
Ongoing advances in cell culture techniques and drug discovery technology are only now facilitating an increase in antiviral R&D and new product launches are driving market growth and commercial interest in certain viral indications.
While each viral indication, ranging from HIV to influenza, presents unique challenges, there are a number of issues that companies developing and marketing drugs across this field face. Curative therapies are rare, drug resistance is becoming increasingly problematic and the introduction of novel vaccines threatens the market for many antivirals.
Scope of this Report:
- Detailed analysis of the global antiviral market, focusing on HIV, hepatitis, herpes and influenza
- Assessment of each viral indication, characterized by 2002 market value, forecasted growth and current clinical unmet need
- Insight into antiviral research and development activity
- Discussion of the various options for more effective life cycle and portfolio management strategy
Report Highlights:
- The antiviral market is set to demonstrate positive growth up until 2011, driven predominantly by the increased availability of hepatitis B treatments.
- Growing disease awareness, particularly of recently characterized infections, such as HCV, will continue to drive patient potential by increasing presentation rates.
- Broad-spectrum antivirals present companies with good opportunities to implement life-cycle management initiatives.
Key Reasons to Buy this Report:
- Determine the characteristics that define antiviral markets and their relative potential
- Understand the key drivers and resistors of antiviral market growth
- Identify life-cycle management options that help to optimize and extend product revenue
'. Relative to other therapeutic areas, commercial attractiveness of the antiviral market is high and set to increase, mainly driven by novel HIV and hepatitis B products.'
Customers who bought this item also bought
Respiratory Syncytial Virus: Can Antivirals Make the Grade?
The Antivirals Market Outlook: Market Analysis of Future Growth and Leading Players by Sector
Herpes And Respiratory Antivirals - Leaders Rise And Fall
Human Papillomavirus - Vaccines, Then Antivirals?
The Antivirals Outlook To 2007: Marketing Opportunities By Disease State, Patient Potential And Product Profile
Strategic Perspectives 2001: The Antiviral Market - A Market For Expanding Indications
Phosphodiesterases: A Drug Target Family with Broad Therapeutic Impact
Pipeline Perspectives: Hepatitis B and C - Antivirals Challenge the Interferons?
|
|
|
|
